Immune Checkpoint Inhibitor Side Effects: Rising Incidence, Stable Mortality & High-Risk Events

A recent international study highlights potential risks associated with immunotherapy, a cancer treatment that has significantly improved outcomes for many patients. Whereas immunotherapy, specifically treatments using immune checkpoint inhibitors (ICIs), has become a cornerstone in cancer care, researchers have found that serious adverse events (side effects) linked to these therapies are increasing in frequency, though mortality rates remain relatively stable. The findings underscore the importance of careful monitoring and prompt management of complications in patients receiving ICIs.

Immune Checkpoint Inhibitors: How They Function and Why Monitoring Matters

Immune checkpoint inhibitors work by releasing a natural “brake” on the immune system, allowing it to recognize and attack cancer cells more effectively. As explained by the Memorial Sloan Kettering Cancer Center, these therapies essentially unleash the body’s own defenses against tumors. Learn more about checkpoint inhibitors at MSKCC. Although, this unleashed immune response can sometimes turn against healthy tissues, leading to a range of side effects affecting multiple organs. These side effects, while manageable in many cases, can be severe and even life-threatening.

The study, a retrospective analysis of data from over 290,000 cases reported to both the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO), examined adverse events related to ICI treatment between 2012 and 2023. The researchers observed an increase in the annual frequency of these events, which is expected given the growing use of immunotherapy. Importantly, the overall mortality rate associated with these adverse events has remained around 25% during that period.

Identifying High-Risk Adverse Events

The research team developed an algorithm to analyze the reported data and identified approximately 20% of ICI-related adverse events that carry a particularly high risk of mortality. Specifically, they found that 36% of patients experiencing certain adverse events died, compared to 11% of those with other ICI-related complications. The 63 adverse events identified as highly fatal encompass a broad spectrum of conditions, including respiratory issues, cardiac problems, muscle inflammation, vascular events, liver damage, and infections. The National Cancer Institute provides further information on immunotherapy and its side effects.

This identification of high-mortality adverse events is crucial for establishing targeted surveillance measures for patients undergoing ICI therapy. By recognizing which complications pose the greatest risk, clinicians can implement more proactive monitoring strategies and improve the management of these potentially life-threatening events.

What Does This Mean for Patients and Clinicians?

The study reinforces observations previously noted in clinical practice, such as the risk of pneumonitis (lung inflammation), hepatitis (liver inflammation), and myositis (muscle inflammation) associated with ICI treatment. The current research provides a broader, global epidemiological perspective on these risks. The findings are particularly relevant to a range of medical specialties, including pulmonology, cardiology, hepatology, neurology, and rheumatology, as these specialists often collaborate with oncologists in the care of cancer patients experiencing ICI-related adverse events.

It’s important to note that the study is retrospective, meaning it analyzed data that was already collected. This type of study can identify associations between ICI treatment and adverse events, but it cannot definitively prove that the treatment *caused* those events. As the study authors acknowledge, it can be difficult to differentiate between mortality directly attributable to the ICI, mortality resulting from the underlying cancer, or mortality from other contributing factors. The study reflects overall mortality and doesn’t isolate the specific contribution of the ICI.

Understanding the Nuances of Risk

While the 25% mortality rate associated with ICI-related adverse events sounds alarming, it’s crucial to consider this figure in context. The study doesn’t provide information on the overall survival rates of patients receiving ICI therapy, which are often significantly improved compared to traditional cancer treatments. The benefits of immunotherapy must be weighed against the potential risks, and this decision should be made on an individual basis in consultation with a qualified oncologist.

the study highlights the variability in risk among different types of adverse events. The fact that some complications are associated with a much higher mortality rate than others underscores the importance of early detection and targeted management strategies. The American Cancer Society offers detailed information on immune checkpoint inhibitors and their potential side effects.

The Evolving Landscape of Immunotherapy Safety

The findings from this study will likely inform ongoing efforts to improve the safety of immunotherapy. Researchers are continually working to identify biomarkers that can predict which patients are most likely to experience adverse events, and to develop strategies to prevent or mitigate these complications. Pharmacovigilance systems, like those used to collect the data for this study, play a critical role in monitoring the safety of latest therapies and identifying emerging risks.

Looking ahead, several additional checkpoint inhibitor drugs are currently under investigation in clinical trials at institutions like Memorial Sloan Kettering Cancer Center. These trials aim to expand the use of immunotherapy to a wider range of cancers and to improve the efficacy and safety of existing treatments. Ongoing research and surveillance will be essential to ensure that immunotherapy remains a safe and effective option for cancer patients.

Next Steps: Clinicians should remain vigilant for potential adverse events in patients receiving ICI therapy, particularly those identified as high-risk in this study. Continued data collection and analysis through pharmacovigilance systems will be crucial for refining our understanding of the risks and benefits of immunotherapy and for optimizing patient care.